Summary The expression of p53 protein was immunohistochemically studied in formalin-fixed paraffinembedded biopsy specimens of 203 colorectal carcinomas by use of a monoclonal antibody specific for the p53 protein, PAbl8OL. p53 protein expression with its reactivity localised in nuclei was found in 121 (59.6%) of the cancers. There was no correlation of pS3 immunoreactivity with histological classification, wall invasion, lymphatic invasion, venous invasion, lymph node metastases, or peritoneal metastases. p53-positive cancers were more frequently associated with liver metastasis than p53-negative ones. Patients with p53-positive tumours had significantly poorer prognoses than those with p53-negative tumours. The 5 year survival rate was 58.1 % for patients with p53-positive tumours, and 76.3% for those with p53-negative tumours. In Dukes' stage C tumours, an especially good correlation was found between p53 immunoreactivity and prognosis. In addition, patients with p53-positive tumours had higher recurrence rates. The results indicate that p53 immunoreactivity may be a useful prognostic marker of colorectal cancers.
Germline or somatic inactivation of tumour suppressor genes through point mutation or deletion plays an important role in carcinogenesis. p53, one of these tumour suppressor genes, is a cellular protein discovered through its association with DNA virus antigen in murine cells (Lane & Crawford, 1979) . This protein may be localised in different cellular compartments in normal and in transformed cells (Rotter et al., 1983) . The p53 protein in normal cells, or p53 of the wild type, restrains cell growth, and probably acts as a tumour suppressor (Fearon & Vogelstein, 1990 ; Lane & Benchimol, 1990 , Levine, 1990 ). Crawford et al. (1981) reported that many human tumour-derived cell lines show elevated levels of p53 protein. In addition, the p53 protein in tumourderived cell is explained as the mutated forms of p53 (Lane & Benchimol, 1990) . Also, a mutant p53 with an extended half-life induces progression of growth-arrested, resting cells to an active, cycling state, and causes immortalisation of normal cells and their malignant transformation in cooperation with H-ras oncogene (Mercer et al., 1982 , Reich & Levine, 1984 Parada, 1984) . p53 expression has been reported in a number of human tumours, including those of the breast, lung and colorectum (Crawford, 1984; Cattoretti, 1988; Iggo, 1990) . Several authors have recently shown the relationship between p53 overexpression and prognosis in breast cancer (Cattoretti et al., 1988; Iwaya et al., 1991) The biopsy and resected specimens of the 203 lesions were fixed in 10% formalin overnight and embedded in paraffin. Thirty-nine surgically resected specimens were fixed by the AMeX (acetone, methyl benzoate, and Xylene) method (Sato et al., 1986) (Figure 1 ). In 39 of the patients, p53 immunoreactivity could be determined in both formalin-fixed paraffin-embedded biopsy specimens and AMeX fixed paraffin-embedded resected ones; and 35 (89.8%) of them had the same pattern of p53 immunoreactivity in both specimens. More precisely, 23 of the patients had p53-positive tumours and 12, p53-negative tumours in both resected and biopsy specimens, while the other four (10.2%) differed in p53 immunoreactivity: three had p53-negative biopsy specimens and p53-positive resected specimens, and another, p53-positive biopsy specimens and p53-negative resected specimens (Table I) .
The relationship between p53 protein expression and clinicopathological findings is shown in Table II . There was no correlation between p53 protein expression and histological (Table III) . There was no significant correlation between Dukes' stages and p53 immunoreactivity. Figure 2 depicts the Kaplan-Meier curves for the survival of these two groups of patients. The 5-year survival rate was 76.3% for 82 patients with p53-negative tumours. However, the prognosis was poor in 121 patients with p53-positive tumours, and the 5-year survival rate was 58.1% for this group. The difference between these two groups was statistically significant (P<0.05). Among the patients with Dukes' stage A and B tumours, no difference was found in survival between the patients with p53-positive and those with p53-negative tumours, with the 5-year survival rates of 96.5% and 95.5%. Furthermore, there was no significant difference between the survival rates and the patterns of p53 immunoreactivity in patients with Dukes' stage D tumours. Among the 55 patients with Dukes' stage C tumours, however, those with p53-negative tumours survived significantly longer than those with p53-positive tumours (P<0.05) (Figure 3) . The 5-year survival rates were 59.2% for 26 patients with p53-positive tumours, and 88.9% for those with p53-negative tumours. In 148 patients who underwent curative resection we examined the relationship between recurrence rate and p53 immunoreactivity. The patients with p53-negative tumours gave a recurrence rate of 7.6%, while those with p53-positive tumours recorded a recurrence rate of 18.3% the difference between the two groups was statistically significant (P <0.05).
In flow cytometric analysis, DNA diploidy (diploid) was detected in 52 (40.3%) of 129 patients, and 77 (59.7%) of the patients had tumours with DNA aneuploidy containing an abnormal DNA stemline (aneuploid). Forty-nine patients with p53-negative tumours consisted of 21 with diploid and 28 with aneuploid tumours, while 80 patients with p53-positive tumours were composed of 31 with diploid and 49 with aneuploid tumours. There was no correlation between the p53 immunoreactivity and the DNA ploidy pattern (Table IV) . (Banks et al., 1986 ).
PAbl801 is reactive on both the wild type and mutant forms of p53. However, the level of wild type p53 is low, with a short half-life (Oren et al., 1981; Reich et al., 1983 (Yamaguchi, 1992) . In addition, Kern et al. (1989) reported that deletion of 17p and that of 18q were significantly associated with distant metastasis and prognosis. Knowing the malignant potential preopera-I tively is important in choosing an adequate therapeutic method and in prognosis. We have therefore studied p53 immunoreactivity in endoscopic biopsies of colorectal cancer. There was no significant correlation between p53 immunoreactivity and histological classification, wall invasion, lymphatic invasion, venous invasion, lymph node metastases, or peritoneal metastases. Previous immunohistochemical studies of p53 described no significant correlation between p53 expression and site, differentiation, or Dukes' stage (Purdie, 1991) . In our study, however, the patients with p53-positive tumours had a higher rate of liver metastases. In addition, p53 immunoreactivity showed a close inverse correlation with prognosis. By Dukes' staging, the 5-year survival rate of patients with Dukes' stage A and B tumour was over 90%, while the prognosis was very poor in patients with Dukes' stage D. Therefore, there was no significant correlation between p53 immunoreactivity and prognosis in Dukes' A, B and D cases. However among the patients with Dukes' stage C cancers, survival was significantly shorter when the tumour was p53-positive. Furthermore, the patients with p53-positive tumours had a greater relative risk of recurrence. In general, aneuploid tumours are associated with poor prognosis (Wolley et al., 1982; Armitage et al., 1985) . Here, however, we show no correlation between p53 immunoreactivity and DNA ploidy an observation similar to that of Scott et al. (1991) . However, we previously reported that the growth fraction of p53-positive tumours is significantly higher than that of p53-negative tumours (Yamaguchi, 1992) . Also, we argued that the detection of growth fraction by use of a monoclonal antibody against DNA polymerase a enables the measurement of proliferative activity, and that the growth fraction of colorectal cancers is a useful prognostic indicator. We suggested therefore that the poor survival of patients with p53-positive tumours might be associated with a high cell proliferative activity. From the findings, it may be concluded that the p53 immunoreactivity detected by use of PAbl801 is a useful prognostic indicator of colorectal cancers, and that it would permit the preoperative analysis of biopsy specimens.
